Overview
During fellowship training I developed a passion for pediatric patients with hematologic malignancies (lymphoblastic leukemia, myeloid leukemia, myeloproliferative disorders) and the nuanced treatment approaches required to treat these patients. My research focuses on the reduction of chemotherapy-associated toxicities through understanding of patient-specific risk factors and the development of improved supportive care and family education based upon this understanding.
Office Hours
Every Monday and Tuesday 1pm-5pm
1st, 3rd and 5th Tuesday 8am-12pm
2nd and 4th Wednesday 1pm-5pm
1st, 3rd and 5th Tuesday 8am-12pm
2nd and 4th Wednesday 1pm-5pm
Current Appointments & Affiliations
Assistant Professor of Pediatrics
·
2025 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Recent Publications
Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma
Journal Article Radiation Oncology · August 21, 2025 Full text CiteHigher Rates of Hypersensitivity Reactions to Calaspargase Compared With Pegaspargase: A Single Center Retrospective Review.
Journal Article Pediatr Blood Cancer · May 2025 BACKGROUND: Asparaginase is a critical component of curative therapy for the treatment of pediatric acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Pegaspargase (PEG) increased the duration of asparagine depletion and lowered the ... Full text Link to item CiteFibroblast Growth Factor Receptor 1 Rearranged Myeloproliferative Neoplasm (MLN-FGFR1) in a Pediatric Patient; Challenging Diagnosis and Treatment Approach
Journal Article Blood · November 5, 2024 Myeloproliferative neoplasms driven by Fibroblast Growth Factor Receptor 1 mutations (MLN-FGFR1) are rare, with less than 110 cases reported in literature worldwide1,2. Chromosomal abnorm ... Full text CiteEducation, Training & Certifications
Kansas City University of Medicine and Biosciences ·
2019
D.O.